AI Article Synopsis
- - The study investigates clinical and epidemiological features of Vogt-Koyanagi-Harada (VKH) disease in Spain, analyzing data from 112 patients over a minimum of six months.
- - The majority of participants were women (83.9%) with an average age of 37.5 years; the disease was often classified as incomplete acute, with corticosteroids being the most common treatment.
- - Findings indicate that VKH patients generally experience good visual outcomes, though complications like cataracts and ocular hypertension are prevalent.
Article Abstract
Purpose: To describe the clinical and epidemiological characteristics of patients with Vogt-Koyanagi-Harada (VKH) disease in Spain.
Methods: This was a retrospective multicenter analysis of data from VKH patients followed for at least 6 months. The data collected were related to demographics, clinical manifestations, treatments, and complications.
Results: Participants were 112 patients (224 eyes), from 13 tertiary referral centers, of mean age 37.5 ± 14.7 years; 83.9% were women. Ethnicities were 61.6% Caucasian and 30.4% Hispanic. The disease was classified as complete in 16.1%, incomplete in 55.4%, and probable in 28.6%. When seen for the first time, the clinical course was acute in 69.6%, recurrent chronic in 15.2%, and chronic in 14.3%. The most frequent treatment was corticosteroids (acute stage 42.2%, maintenance stage 55.6%). The most common complications were cataract (41.1%) and ocular hypertension (16.1%). In most eyes, visual acuity was improved (96.7%) or remained stable at the end of follow up.
Conclusion: VKH in Spain mostly affects women and presents as incomplete acute stage disease. Visual prognosis is good. Cataract and glaucoma are the two most frequent complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/11206721211033477 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!